[Tyr4]-Bombesin
CAS No. 67338-70-9
[Tyr4]-Bombesin( ——— )
Catalog No. M42098 CAS No. 67338-70-9
[Tyr4]-Bombesin is a Bombesin analogue, is a ligand of gastrin-releasing peptide receptor (GRPR).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
Biological Information
-
Product Name[Tyr4]-Bombesin
-
NoteResearch use only, not for human use.
-
Brief Description[Tyr4]-Bombesin is a Bombesin analogue, is a ligand of gastrin-releasing peptide receptor (GRPR).
-
Description[Tyr4]-Bombesin is a Bombesin analogue, is a ligand of gastrin-releasing peptide receptor (GRPR).
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number67338-70-9
-
Formula Weight1669.9
-
Molecular FormulaC74H108N24O19S1
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Joseph Lau, et al. Effect of Radiometal on Binding Affinity and Biodistribution of ProBOMB1, a Novel Bombesin Derivative. Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1013.
molnova catalog
related products
-
Gallic acid trimethy...
Used as a medicine, organic synthesis intermediates.
-
Prepro VIP (111-122)...
Prepro VIP (111-122) (human)
-
Ladiratuzumab
LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.
Cart
sales@molnova.com